Fig. 7: tsRNA-0032/PKM2 signaling axis is involved in lymphangiogenesis in vivo.
From: Targeting glycolytic reprogramming by tsRNA-0032 for treating pathological lymphangiogenesis
A C57BL/6 mice were administered negative control (NC) agomir, tsRNA-0032 agomir, tsRNA-0032 combined with PKM2 null vector, tsRNA-0032 combined with PKM2 overexpression vector, or treated with shikonin, followed by corneal suture placement. Neolymphatic vessels in the flat-mounted corneas were visualized using the fluorescence signal of LYVE-1. Scale bar: 200 μm. B Quantification of neolymphatic vessel coverage area and total length was performed. n = 5; One-way ANOVA followed by post hoc Bonferroni test; *P < 0.05 versus Ctrl group.
